Aung H. Naing

Oncology

210 Ashville Ave # 408
Cary, NC 27518

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 387 publications

Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer.

Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer.

Journal: JAMA network open

Published: July 16, 2026

Ice Nucleation Activity by Fusarium tricinctum Can Enhance Cold Stress: A Potential Contributor to Cold Injury in Apple Trees.

Ice Nucleation Activity by Fusarium tricinctum Can Enhance Cold Stress: A Potential Contributor to Cold Injury in Apple Trees.

Journal: Mycobiology

Published: July 10, 2026

Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.

Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.

Journal: Journal for immunotherapy of cancer

Published: May 28, 2026

CT-Based Deep Foundation Model for Predicting Immune Checkpoint Inhibitor-Induced Pneumonitis Risk in Lung Cancer.

CT-Based Deep Foundation Model for Predicting Immune Checkpoint Inhibitor-Induced Pneumonitis Risk in Lung Cancer.

Journal: medRxiv : the preprint server for health sciences

Published: May 04, 2026

First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies.

First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies.

Journal: Journal for immunotherapy of cancer

Published: April 27, 2026

Clinical determinants of survival outcomes and acute toxicity after adoptive cellular therapy for solid tumors.

Clinical determinants of survival outcomes and acute toxicity after adoptive cellular therapy for solid tumors.

Journal: Frontiers in immunology

Published: April 06, 2026

Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies.

Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies.

Journal: Journal for immunotherapy of cancer

Published: March 26, 2026

Genomic co-alterations and immune-related adverse events shape outcomes of thymic malignancies treated with immune checkpoint inhibitors.

Genomic co-alterations and immune-related adverse events shape outcomes of thymic malignancies treated with immune checkpoint inhibitors.

Journal: NPJ precision oncology

Published: March 10, 2026

Tumor microenvironment changes after treatment with avelumab and immune-stimulating agent combinations in patients with advanced solid tumors.

Tumor microenvironment changes after treatment with avelumab and immune-stimulating agent combinations in patients with advanced solid tumors.

Journal: Research square

Published: February 06, 2026

Tumor microenvironment changes after treatment with avelumab and immune- stimulating agent combinations in patients with advanced solid tumors.

Tumor microenvironment changes after treatment with avelumab and immune- stimulating agent combinations in patients with advanced solid tumors.

Journal: Research square

Published: February 06, 2026

DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix.

DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix.

Journal: Journal for immunotherapy of cancer

Published: January 20, 2026

Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study.

Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study.

Journal: NPJ precision oncology

Published: December 10, 2025

Showing 1-12 of 387

Last Updated: 09/26/2026